Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_1
1
20%
Ph phase_2
2
40%
Ph phase_3
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated2
Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

completed120%
terminated240%
withdrawn240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

NCT04171219
withdrawnphase_2

Talabostat in Treating Patients With Metastatic Kidney Cancer

NCT00489710
withdrawnearly_phase_1

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

NCT04123574
completedphase_1

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

NCT00303940
terminatedphase_3

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00243204

Clinical Trials (5)

Showing 5 of 5 trials
NCT04171219Phase 2

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Terminated
NCT00489710Phase 2

Talabostat in Treating Patients With Metastatic Kidney Cancer

Withdrawn
NCT04123574Early Phase 1

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Withdrawn
NCT00303940Phase 1

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

Completed
NCT00243204Phase 3

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5